Načítá se...

Safety of intravenous immunoglobulin treatment.

In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Atrah, H I, Crawford, R J, Dow, B C, Mitchell, R
Médium: Artigo
Jazyk:Inglês
Vydáno: 1985
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC499468/
https://ncbi.nlm.nih.gov/pubmed/3932489
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!